



O A N L

OXFORD AMERICAN NEUROLOGY LIBRARY



# Multiple Sclerosis

Clinician's Guide to Diagnosis  
and Treatment

2nd Edition

GARY L. BIRNBAUM, M.D.



O A N L

OXFORD AMERICAN NEUROLOGY LIBRARY

---

# Multiple Sclerosis

This material is not intended to be, and should not be considered, a substitute for medical or other professional advice. Treatment for the conditions described in this material is highly dependent on the individual circumstances. And, while this material is designed to offer accurate information with respect to the subject matter covered and to be current as of the time it was written, research and knowledge about medical and health issues is constantly evolving and dose schedules for medications are being revised continually, with new side effects recognized and accounted for regularly. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulation. Oxford University Press and the authors make no representations or warranties to readers, express or implied, as to the accuracy or completeness of this material, including without limitation that they make no representation or warranties as to the accuracy or efficacy of the drug dosages mentioned in the material. The authors and the publishers do not accept, and expressly disclaim, any responsibility for any liability, loss or risk that may be claimed or incurred as a consequence of the use and/or application of any of the contents of this material.

O A N L

OXFORD AMERICAN NEUROLOGY LIBRARY

---

# Multiple Sclerosis

## Clinician's Guide to Diagnosis and Treatment

**Edited by**

**Gary Birnbaum, MD**

Director, Multiple Sclerosis Treatment and Research Center  
Minneapolis Clinic of Neurology  
Clinical Professor of Neurology  
University of Minnesota School of Medicine  
Minneapolis, MN



OXFORD

UNIVERSITY PRESS

# OXFORD

UNIVERSITY PRESS

Oxford University Press is a department of the University of Oxford.  
It furthers the University's objective of excellence in research, scholarship,  
and education by publishing worldwide.

Oxford New York

Auckland Cape Town Dar es Salaam Hong Kong Karachi

Kuala Lumpur Madrid Melbourne Mexico City Nairobi

New Delhi Shanghai Taipei Toronto

With offices in

Argentina Austria Brazil Chile Czech Republic France Greece

Guatemala Hungary Italy Japan Poland Portugal Singapore

South Korea Switzerland Thailand Turkey Ukraine Vietnam

Oxford is a registered trademark of Oxford University Press in the UK  
and certain other countries.

Published in the United States of America by

Oxford University Press

198 Madison Avenue, New York, NY 10016

© Oxford University Press 2013

All rights reserved. No part of this publication may be reproduced, stored in a  
retrieval system, or transmitted, in any form or by any means, without the prior  
permission in writing of Oxford University Press, or as expressly permitted by law,  
by license, or under terms agreed with the appropriate reproduction rights organization.  
Inquiries concerning reproduction outside the scope of the above should be sent to the  
Rights Department, Oxford University Press, at the address above.

You must not circulate this work in any other form  
and you must impose this same condition on any acquirer.

Library of Congress Cataloging-in-Publication Data

Birnbaum, Gary. Multiple sclerosis : clinician's guide to diagnosis and  
treatment / Gary Birnbaum. — 2nd ed.

p. : cm. — (Oxford American neurology library)

Includes bibliographical references and index.

ISBN 978-0-19-984078-6

I. Title. II. Series: Oxford American neurology library.

[DNLM: 1. Multiple Sclerosis. WL 360]

616.8'34—dc23 2012022543

9 8 7 6 5 4 3 2 1

Printed in the United States of America  
on acid-free paper

# Contents

Acknowledgment	ix
Introduction	xi
<b>1. A Brief History of Multiple Sclerosis</b>	<b>1</b>
Experimental Autoimmune Encephalomyelitis	2
<b>2. Factors Involved in Causing Multiple Sclerosis</b>	<b>5</b>
Epidemiology	5
Causes of MS	6
Immunology	8
<b>3. The Patterns and Pathophysiology of MS</b>	<b>13</b>
Patterns of MS	13
Pathophysiology of MS	17
<b>4. Imaging of the Central Nervous System in Multiple Sclerosis</b>	<b>23</b>
Standard X-Ray Imaging of the Skull and Spinal Column	23
Computed Tomography (CT) Imaging of the CNS	23
Magnetic Resonance Imaging	23
<b>5. Making a Diagnosis of Multiple Sclerosis</b>	<b>35</b>
Patterns of Disease Presentation	35
Demographics	36
Genetics of MS	36
Initial Clinical Symptoms in Persons with Relapsing-Remitting MS	37
Initial Clinical Symptoms of Primary-Progressive MS	40
Presenting Signs in Multiple Sclerosis	40
Magnetic Resonance Imaging	41
Evoked Responses	44
Cerebrospinal Fluid Analysis	44
Ruling Out MS “Look-alikes”	46
Algorithms for the Diagnosis of MS	51
Imparting a Diagnosis of MS	54

<b>6. Complications and Comorbidities of Multiple Sclerosis</b>	<b>59</b>
Loss of Bone Density (Osteopenia or Osteoporosis)	59
Sleep Apnea and Other Altered Sleep Patterns	61
Mood Disturbances	62
Urinary Tract and Other Infections	63
Sexual Dysfunction	65
Skin Lesions	66
Joint Dysfunction	67
Obesity	67
<b>7. Relapses of Multiple Sclerosis and Their Treatment</b>	<b>71</b>
What Constitutes a Relapse?	71
Conventional Relapse Treatments	71
Unconventional Relapse Treatments	75
Relapse Prevention	75
<b>8. Long-Term Disease-Modifying Therapies</b>	<b>79</b>
Issues with Long-Term Immune-Modulating Therapies	79
Choosing a Disease-Modifying Therapy	79
Ensuring Treatment Adherence and Compliance	80
When Do I Initiate Treatment With Disease-Modifying Therapies?	81
Pregnancy, Breastfeeding, and Disease-Modifying Therapies	82
Beta-Interferons	82
Neutralizing Antibodies to Beta-Interferon	83
Glatiramer Acetate	86
Issues With Glatiramer Acetate	86
Fingolimod	87
Teriflunomide	89
Second-Line Disease-Modifying Therapies	91
Mitoxantrone	91
Natalizumab	92
Switching Disease-Modifying Therapies, or Defining the Insufficient Responder	95
When Should Long-Term Immune-Modulating Therapy Be Stopped?	98
Future Therapies	99

<b>9. Management of Multiple Sclerosis Symptoms</b>	<b>107</b>
Fatigue	107
Depression	121
Pain	121
Spasticity	121
Weakness	121
Bladder, Bowel, and Sexual Dysfunction	122
Cognitive Impairment	123
Conclusion	123
<b>10. Complementary Therapies for Multiple Sclerosis</b>	<b>127</b>
Nurses Certified in the Care of Persons with MS	127
Physical Therapy	127
Exercise Physiologists	129
Occupational Therapy	129
Psychiatrists, Counselors, and Psychologists	129
Neuropsychologists	130
Orthotists	130
Neuro-Ophthalmologists	131
Urologists	131
Social Workers	131
Diet, Nutrition, and Food Supplements	131
<b>11. Gender Issues and Special Multiple Sclerosis Populations</b>	<b>137</b>
Women	137
Menses	137
Disease-Modifying Therapies and Pregnancy	137
Pregnancy	138
Restarting Disease-Modifying Therapy and the Role of Breastfeeding	139
Men	139
Children of Parents with MS	139
Pediatric MS	143
<b>12. Resources</b>	<b>147</b>
Websites	147
Websites for MS Specialty Certification	147
Patient Advocacy Organizations	147



Sites for FDA Approved Disease-Modifying Therapies for Multiple Sclerosis	147
Site for MR Imaging Protocol for MS	148
Patient Books and Materials	148
Index	149

# Acknowledgment

This book would not have been possible without my being privileged to care for the many persons with MS, in some instances over decades. They have taught me all I know about this disease. Their courage, resilience, and optimism in the face of an illness with potentially major consequences have been a continuing source of inspiration and support. I thank them for all they have given me.

Needless to say, my wife, daughter, and her family supported my efforts and indulged me the time away from them to write this book. I thank them too.

Finally, I thank Drs. Benjamin Baker and John Money, two of my professors at Johns Hopkins, who, unbeknownst to them, were role models to me of physicians who provided compassionate, understanding, gentle, and expert care to their patients, and made it look easy.

Gary Birnbaum, MD

*This page intentionally left blank*

# Introduction

Many books have been written on the pathology, immunology, diagnosis, and treatment of persons with multiple sclerosis (MS). Most of these have been directed at neurologists and other specialists in the field, with details commensurate with the expertise of these readers. This book has a different purpose. Its goal is to present a practical and reasonable approach to the diagnosis and treatment of MS to those health professionals most likely to first see persons with MS, namely primary care physicians and clinical nurse specialists. The long-term care of persons with MS often is dependent on the expertise of such non-neurologists, but with the multitude of other illnesses cared for by primary care health professionals, providing a compendium of all known information about MS is not useful. Rather, I hope that this book will provide an algorithm for the diagnosis and treatment of persons with MS, as well as providing a foundation for more detailed readings on the subject.

As is quickly apparent at any meeting of MS experts, there is no one way to manage persons with MS. The variability in disease presentation, disease course, and variety of symptoms mandates an individualized approach. The approaches to be described in this book are those I have found useful over more than thirty years of caring for persons with MS. I don't espouse them as being the only way, but I hope they will serve as a framework for providing the best possible care to our patients.

*This page intentionally left blank*

## Chapter 1

# A Brief History of Multiple Sclerosis

It is not possible to define the biological onset of a disease characterized not only by a particular clinical course but also by particular changes in the central nervous system (CNS; brain and spinal cord), since the technology necessary to look at changes in the CNS was not available until the late 19th century. However, by interpreting biographies and diaries of persons with symptoms suggestive of MS, it is possible to conjecture that MS historically occurred as early as the 14th century.

In a biography of St. Lidwina of Schiedam, symptoms suggestive of a fluctuating, multifocal neurologic illness are described that started in the year 1396 after ice skating. Her subsequent course of increased walking difficulties, with episodes that may have been remissions, suggests that she may have had similar to MS, though this is far from certain. St. Lidwina was canonized in 1890 and is now the patron saint of skaters.

A more robust description of symptoms strongly suggestive of MS is found in the diary of Sir Augustus Frederick d'Este (1794–1848), a grandson of England's King George III. In it he describes exacerbating remitting symptoms suggestive of optic neuritis and double vision, leg weakness, and bowel and bladder difficulties, followed over the years by gradually progressive weakness and spasms that left him bed-bound by the end of his life.

Why is a history of MS put into a book that is meant to be a primer on the diagnosis and care of persons with MS? For two reasons. One is to put into historical context the fact that MS occurred before the appearance of many modern toxins that have been impugned as causes of MS. These include mercury amalgam in tooth fillings (first used in the early 20th century) and environmental lead. That does not mean that environmental factors are unimportant in MS: as will be described in Chapter 2, environmental factors play a major role in disease susceptibility. Rather, in the absence of proof implicating a particular factor, great caution should be used in recommending any "treatments" based on unsupported hypotheses, such as advising persons with MS to have their dental amalgams removed or be detoxified with treatments such as chelation therapy. The second reason for having this chapter is to put into historical context the fact that any treatment for a disease such as MS, which can spontaneously remit, will in some instances appear successful. Many of the treatments received by Sir d'Este, such as bloodletting, leeches to the temples, beefsteaks twice a day, sherry and Madeira wine, rubbing with horsehair gloves, and undergoing a course of electricity, were associated with significant improvement and certainly would have been considered successful therapies by the physicians of that time.

While MS was not recognized as a distinct disease until 20 years after d'Este's death, pathologic descriptions of diseased brain were being made with

increasing frequency. A professor of anatomy, Robert Carswell, in 1838 was the first to note patches of hardened areas of scarring in the brain and spinal cord of persons who now would be classified as having MS. However, there were no clinical correlations. Working independently, the anatomist Jean Cruveilhier (1791–1894), in a book published in 1841, described multifocal areas of scarring in the brain and spinal cord. Cruveilhier was the first person to correlate the pathologic changes with symptoms such as tremors and walking difficulties.

The Parisian neurologist Jean-Martin Charcot (1825–1893), with his colleague Edmé Vulpian, in a series of lectures in 1868 was instrumental in summarizing the observations of the anatomists and defining MS as a separate clinical entity. He also described both demyelination and axonal loss as characteristic pathologic features of the disease. It is said that Charcot saw fewer than 40 cases of MS in his lifetime, including his maid, whom he believed had this illness, and thus considered it rare. Nevertheless, his careful clinical and pathologic observations laid the foundation for much of the work on MS in the subsequent century.

Research into the epidemiology of MS around the world was accelerated by the efforts of the Association for Research in Nervous and Mental Diseases (ARNMD) in 1921, leading to the observations of Lord Russell Brain, who in 1930 was one of the first to describe the uneven geographic distribution of MS.

## Experimental Autoimmune Encephalomyelitis

While MS is an exclusively human disease, much of our understanding of autoimmune phenomena in the CNS is based on an animal model initially called experimental allergic encephalomyelitis (EAE). EAE was, induced by Thomas Rivers in 1935 following immunization of animals with CNS components. While there are major differences between MS and EAE, rodent EAE continues to be used as a model for MS and is used to establish “proof of concept” for potential treatments for MS. Indeed, all current therapies for MS were initially studied in EAE and were shown to be effective before being tested in humans. It is unlikely a therapy in this day and age would ever enter clinical trials without showing prior efficacy in ameliorating EAE. However, the majority of effective treatments of EAE have not proven to be effective when tested in human clinical trials.

EAE has also been useful in helping elucidate some of the presumed mechanisms of action of the disease-modifying therapies, described in Chapter 8. However, since this book is intended to be a practical compilation of data allowing health care providers to provide the best possible care to persons, rather than a compendium of information on all aspects of autoimmune central nervous system disease, a detailed description of changes in EAE induced by disease-modifying therapies is not be presented.

## Further Reading

Brain WR. Critical review: disseminating sclerosis. *Q J Med.* 1930;23:343–391.

Carswell R. *Illustrations of the Elementary Forms of Disease*. London: Longman; 1838 (Plate 1V, Fig. 1).

- Charcot JM. *Lectures on the diseases of the nervous system delivered at La Salpêtrière* (translated from French). London: The New Sydenham Society; 1877:170–177, 182–202.
- Charcot JM. Histologie de la sclérose en plaques. *Gaz Hop (Paris)*. 1868;41:554, 557–558, 566.
- Charcot M. *Lectures on Diseases of the Nervous System* (translated from French). London: The New Sydenham Society; 1881 (vol 1, p. 214).
- Cruveilhier J. *L'Anatomie pathologique du corps humain; descriptions avec figures lithographiées et coloriées: diverses alterations morbides dont le corps humain est susceptible*. Paris: Baillière; 1829–1842 (vol 2; liv 32, Pl 2, pp. 19–24; liv 38, Pl 5, pp. 1–4).
- Firth D. *The Case of Augustus D'Este*. Cambridge: Cambridge University Press; 1948.
- Murray J. Prelude to the framing of a disease: multiple sclerosis in the period before Charcots Lecons. *Int Mult Scler J*. 2004;11(3):79–85.
- Murray J. *Multiple Sclerosis—The History of a Disease*. New York: Demos Medical Publishing; 2005.



*This page intentionally left blank*